Seeka FY23: PBT swung to -$21.0m loss on a kiwifruit volume collapse

What changed

Seeka's FY23 result is best understood against HY23 rather than as a clean prior-year comparison, because the extraction data pairs the full year against the first half. Revenue for the full year came in at $300.9m, with HY23 contributing $212.7m — meaning the implied second half generated only $88.3m of revenue. That half-year shape is the defining feature of this result.

• EBITDA collapsed to $26.0m for the full year, with HY23 contributing $36.4m. The implied H2 EBITDA was therefore negative $10.4m — the full-year headline is flattering relative to the underlying run-rate.
• PBT swung from a $13.6m profit at HY23 to a full-year loss of $21.0m, implying an H2 PBT loss of approximately $34.6m.
• NPAT was a loss of $14.5m for the full year, against a $10.5m profit at HY23. A $6.5m tax credit on the loss reduced the statutory NPAT shortfall versus PBT.
• Gross profit fell to $48.7m (implied gross margin ~16.2%) from $68.3m in FY22, down 29%.
• Operating cash flow of $2.7m was positive for the full year but deteriorated from $4.5m at HY23, implying negative operating cash flow in H2.
• Gross borrowings fell modestly to $177.6m from $182.2m, and the group remained in a net-cash position. Total equity eroded by $12.6m to $260.0m as losses flowed through.
• Post-harvest operations remained the dominant segment at 60.6% of revenue but saw EBIT fall to $25.1m from $37.0m, while Australian operations swung to a loss of $3.1m from a small loss of $0.5m — a segment in clear deterioration.

What matters

1. Volume collapse is the single driver. Seeka explicitly attributed the result to materially lower kiwifruit volumes — an industry-wide phenomenon in the 2023 harvest. Revenue fell to $301m from $348m in FY22 (a 13.6% decline). Because Seeka's cost base carries significant fixed components in post-harvest infrastructure, the operating leverage works sharply in reverse: a 13.6% revenue decline produced a 44% EBITDA decline (vs FY22's $46.1m) and a $21.0m PBT loss versus FY22 profitability. The result was in line with guidance ($20m–$25m loss before tax), which slightly softens the surprise but does not change the magnitude.

2. The H2 shape reveals the structural earnings risk. The kiwifruit harvest is concentrated in the first half, which is why HY23 captured 70.7% of full-year revenue and 140% of full-year EBITDA. In a bad-volume year, the second half — which carries overhead without comparable throughput — becomes a loss-making drag. H2 NPAT of negative $24.9m dwarfed the H1 profit of $10.5m. This seasonality amplifies downside in poor harvest years and is a fundamental feature of the business model, not a one-off anomaly.

3. Australian operations are a growing concern within the portfolio. The Australian segment reported a $3.1m EBIT loss on $10.4m of revenue, implying a negative 30% margin. This deteriorated sharply from a $0.5m loss at HY23. Without remediation details from management, this segment is consuming capital at an accelerating rate against a shrinking revenue base.

Expectations

Management guided to a $20m–$25m loss before tax. The reported $21.0m PBT loss sits comfortably within that range and close to the better end of guidance, which is the most creditable element of this release. Operational execution between orchard and point of sale was described as sound — the loss was volume-driven, not efficiency-driven, which matters for how recoverable the result is in a stronger harvest year.

No forward guidance for FY24 was disclosed in the supplied excerpts, and no forward-work balance was provided. The release offers no quantitative basis for assessing whether FY24 volumes will recover. The 2023 harvest was described as industry-wide in its weakness, which at least suggests the problem is exogenous rather than company-specific. Recovery in FY24 depends entirely on harvest conditions and Zespri pool returns, neither of which Seeka controls.

Capex rose to $22.7m from $11.0m — a 107% increase year on year — which the data attributes to both plant and equipment and bearer plant development. With EBITDA of only $26.0m, this capex intensity is notable and pre-lease free cash flow was marginally positive at roughly $2.6m. Investors should watch whether capex normalises or whether development spend continues at elevated levels during a recovery year.

Quality of result

The result is almost entirely volume-driven rather than reflecting operational deterioration, which supports the view that earnings are recoverable in a stronger harvest year. However, several features reduce confidence in near-term earnings quality:

• EBITDA quality is seasonally distorted. The full-year $26.0m EBITDA headline obscures a negative H2. The business generates a large majority of its earnings in the first half and burns cash in the second, meaning annual EBITDA reported at year-end already embeds the worst half.
• Cash conversion weakened. OCF-to-EBITDA fell to approximately 102.8% from 123% at HY23, and operating cash flow in H2 was negative. Working capital improved (receivable days fell from 73 to 27, inventory days from 25 to 13), but this appears to reflect lower throughput rather than a structural efficiency gain — lower volumes mean lower receivables.
• Tax benefit partially flatters NPAT. The $6.5m tax credit on a $21.0m pre-tax loss produced an effective tax rate of 31.1% on the loss versus 23.2% on the prior period's profit. This is mechanically expected but means the NPAT loss of $14.5m understates the operating reality relative to PBT.
• No dividend was declared, preserving cash at the cost of signalling limited near-term confidence. ROE moved from +3.8% to -5.6%.

The balance sheet is modestly supportive — gross borrowings fell, net-cash position held, and no covenant stress was flagged — but equity has declined and the interest burden on $177.6m of gross debt against $26.0m EBITDA is a ratio that warrants monitoring if EBITDA does not recover.

Unresolved

• FY24 volume outlook. No harvest volume guidance or Zespri crop estimate was disclosed. The entire investment thesis rests on volume recovery, yet the release provides no quantitative anchor for how much of the 2023 shortfall is cyclical versus structural.
• Australian operations trajectory. The $3.1m EBIT loss on $10.4m revenue in Australia worsened sharply in H2. There is no disclosed turnaround plan, exit consideration, or timeline for this segment to reach breakeven.
• Capital structure headroom. With $177.6m in gross borrowings and FY23 EBITDA of $26.0m, the implied net-debt-to-EBITDA ratio on gross borrowings alone is approximately 6.8x. Bank covenant thresholds, facility maturity dates, and available headroom were not disclosed.
• Bearer plant and capex programme scope. The doubling of capex to $22.7m during a loss year raises the question of whether the development programme is contractually committed or discretionary, and what the expected return timeline is.

This briefing cannot assess the probability or magnitude of a 2024 harvest recovery, which is the primary variable determining whether FY23 represents a trough or a structural decline.

Key metrics

Segment breakdown

Analytical metrics

---

This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.